Feng, Xiaodong_ Xie, Hong-Guang - Applying pharmacogenomics in therapeutics-CRC Press (2016)

Recommendations

Info

94 Applying Pharmacogenomics in Therapeutics76. Bhatia R, Holtz M, Niu N, Gray R, Snyder DS, Sawyers CL, Arber DA, Slovak ML,Forman SJ. Persistence of malignant hematopoietic progenitors in chronic myelogenousleukemia patients in complete cytogenetic remission following imatinib mesylatetreatment. Blood 2003;101:4701–7.77. Dohse M, Scharenberg C, Shukla S, Robey RW, Volkmann T, Deeken JF, Brendel C,Ambudkar SV, Neubauer A, Bates SE. Comparison of ATP-binding cassette transporterinteractions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib.Drug Metab Dispos 2010;38:1371–80.
5 Pharmacogenomicsand Laboratory MedicineJianbo J. SongCONTENTSKey Concepts............................................................................................................95Introduction...............................................................................................................96Types of Genetic Variation and Methods of Detection.............................................98Pharmacokinetics....................................................................................................100CYP2D6............................................................................................................. 101CYP2C9.............................................................................................................. 102CYP2C19............................................................................................................ 103CYP3A4 and CYP3A5........................................................................................ 103Other Drug-Metabolizing Enzymes: TPMT, NAT, and UGT1A1.......................... 104Thiopurine Methyltransferase............................................................................ 104N-Acetyltransferase........................................................................................... 105UDP-Glucuronosyltransferase 1A1................................................................... 106Drug Transporters................................................................................................... 107ABCB1............................................................................................................... 108Breast Cancer Resistance Protein...................................................................... 109Organic Anion–Transporting Polypeptides........................................................ 110Pharmacodynamics................................................................................................. 111Pharmacogenomics of Targeted Cancer Therapies................................................. 112BCR-ABL............................................................................................................ 113HER2 Testing in Breast Cancer.......................................................................... 114Lung Cancer Therapy Targets................................................................................. 117EGFR Mutations in Lung Cancer...................................................................... 117ALK Rearrangement in NSCLC........................................................................ 119Genetic Testing for Inherited Cancer Susceptibility............................................... 121Summary................................................................................................................. 130Study Questions...................................................................................................... 131References............................................................................................................... 132KEY CONCEPTS• Genetics is estimated to account for 20–95% of differences in drug efficacyand adverse side effects.• Pharmacogenomics studies and applies information of genetic variants intoclinical practice of drug administration and disease treatment.95
Page 1:
ApplyingPharmacogenomicsin Therapeu
Page 5 and 6:
ApplyingPharmacogenomicsin Therapeu
Page 7:
DedicationWe dedicate this book to
Page 10 and 11:
viiiContentsChapter 10 Pharmacogeno
Page 13 and 14:
EditorsXiaodong Feng, PhD, PharmD,
Page 15 and 16:
ContributorsWeiguo Chen, PhDDepartm
Page 17 and 18:
1Concepts inPharmacogenomics andPer
Page 19 and 20:
Concepts in Pharmacogenomics and Pe
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
2Principles ofPharmacogeneticBiotec
Page 51 and 52:
Principles of Pharmacogenetic Biote
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
Page 59 and 60: Principles of Pharmacogenetic Biote
Page 65: Principles of Pharmacogenetic Biote
Page 68 and 69: 52 Applying Pharmacogenomics in The
Page 91 and 92: 4 ApplyingPharmacogenomicsin Drug D
Page 93 and 94: Applying Pharmacogenomics in Drug D
Page 109: Applying Pharmacogenomics in Drug D
Page 113 and 114: Pharmacogenomics and Laboratory Med
Page 157: Pharmacogenomics and Laboratory Med
Page 160 and 161:
144 Applying Pharmacogenomics in Th
Page 162 and 163:
Page 164 and 165:
Page 166 and 167:
Page 168 and 169:
Page 170 and 171:
Page 172 and 173:
Page 174 and 175:
Page 176 and 177:
Page 178 and 179:
Page 180 and 181:
Page 182 and 183:
Page 184 and 185:
Page 186 and 187:
Page 188 and 189:
Page 190 and 191:
Page 192 and 193:
Page 194 and 195:
Page 196 and 197:
Page 198 and 199:
Page 200 and 201:
Page 202 and 203:
Page 204 and 205:
Page 206 and 207:
Page 208 and 209:
Page 210 and 211:
Page 212 and 213:
Page 214 and 215:
Page 217 and 218:
8Clinical Applicationsof Pharmacoge
Page 219 and 220:
Pharmacogenomics of CNS Disorder Tr
Page 221 and 222:
Page 223 and 224:
Page 225 and 226:
Page 227 and 228:
Page 229 and 230:
Page 231 and 232:
Page 233 and 234:
Page 235 and 236:
Page 237 and 238:
9 ApplyingPharmacogenomicsin the Th
Page 239 and 240:
Applying Pharmacogenomics in the Th
Page 241 and 242:
Page 243 and 244:
Page 245 and 246:
Page 247 and 248:
Page 249 and 250:
Page 251 and 252:
Page 253 and 254:
Page 255 and 256:
Page 257 and 258:
Page 259 and 260:
10Pharmacogenomics andAlternative M
Page 261 and 262:
Pharmacogenomics and Alternative Me
Page 263 and 264:
Page 265 and 266:
Page 267 and 268:
Page 269 and 270:
Page 271 and 272:
Page 273 and 274:
Page 275 and 276:
Page 277 and 278:
Page 279 and 280:
Page 281 and 282:
Page 283 and 284:
Page 285 and 286:
Page 287 and 288:
11 PharmacoeconogenomicsA Good Marr
Page 289 and 290:
Pharmacoeconomics of Pharmacogenomi
Page 291 and 292:
Page 293 and 294:
Page 295 and 296:
Page 297 and 298:
Page 299 and 300:
Page 301 and 302:
Page 303 and 304:
5’3’5’3’ 5’3’ 5’3’3
Page 305 and 306:
1 2 3 4 5Vysis LSI BCR/ABL + 9q34 t
Page 307:
BIOMEDICAL SCIENCEApplying Pharmaco
show all

Feng, Xiaodong_ Xie, Hong-Guang - Applying pharmacogenomics in therapeutics-CRC Press (2016)

Create successful ePaper yourself

Delete template?

Save as template?